

HR 5623

The Insulin Cost Reduction Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 19, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 20, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/5623>

Sponsor

Name: Rep. Grothman, Glenn [R-WI-6]

Party: Republican • **State:** WI • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Jacobs, Chris [R-NY-27]	R · NY		Nov 2, 2021
Rep. Allen, Rick W. [R-GA-12]	R · GA		Mar 8, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 20, 2021
Ways and Means Committee	House	Referred to	Oct 19, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Oct 19, 2021)

The Insulin Cost Reduction Act

This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.

Actions Timeline

- **Oct 20, 2021:** Referred to the Subcommittee on Health.
- **Oct 19, 2021:** Introduced in House
- **Oct 19, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 19, 2021:** Referred to the Subcommittee on Health.